ALNEV — Neovacs SA Income Statement
0.000.00%
Last trade - 00:00
- €0.00m
- -€4.69m
- €0.00m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | FAS | — | FAS | — | FAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.03 | 0.023 | 0.001 |
Cost of Revenue | |||||
Gross Profit | -0.327 | -0.263 | -0.09 | -0.462 | -0.576 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.1 | 9.09 | 4.59 | 10.6 | 7.47 |
Operating Profit | -13.1 | -9.09 | -4.56 | -10.6 | -7.47 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.6 | -9.3 | -6.68 | -12.5 | -4.35 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.8 | -7.55 | -6.14 | -11.8 | -3.55 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.8 | -7.55 | -6.14 | -11.8 | -3.55 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.8 | -7.55 | -6.14 | -11.8 | -3.55 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -76,989,635,357 | -34,514,887,750 | -6,485,211,845 | -403,083,720 | -954,602 |
Dividends per Share |